If you have been reading about Working solution and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
From 1967 to 1993, almost all paclitaxel produced was derived from bark of the Pacific yew, Taxus brevifolia, the harvesting of which kills the tree in the process. The processes used were descendants of the original isolation method of Monroe Wall and Mansukh Wani; by 1987, the U.S. National Cancer Institute (NCI) had contracted Hauser Chemical Research of Boulder, Colorado, to handle bark on the scale needed for phase II and III trials. While both the size of the wild population of the Pacific yew and the magnitude of the eventual demand for paclitaxel were uncertain, it was clear that an alternative, sustainable source of the natural product would be needed. Initial attempts to broaden its sourcing used needles from the tree, or material from other related Taxus species, including cultivated ones, but these attempts were challenged by the relatively low and often highly variable yields obtained. Early in the 1990s, coincident with increased sensitivity to the ecology of the forests of the Pacific Northwest, paclitaxel was extracted on a clinically useful scale from these sources.
Commissioned by the Science Research Council and authored by Sir James Lighthill, the report provided a highly critical assessment of AI research, arguing that it had failed to achieve its "grandiose objectives". The report led to a severe reduction in government funding for AI in the UK, precipitating what is often referred to as the first "AI winter". In response to Japan's Fifth Generation Computer Systems initiative, the UK government launched the Alvey Programme in 1983. This five-year, £350 million collaborative R&D initiative aimed to revitalize the British IT sector, with a significant focus on Intelligent Knowledge Based Systems (IKBS), or expert systems. While the programme succeeded in fostering collaboration between academia and industry, it struggled to translate pre-competitive research into commercial success, leading to a second period of reduced funding and enthusiasm in the late 1980s and early 1990s. The modern era of UK AI research is characterised by significant breakthroughs in deep learning and reinforcement learning, commercialised by the London-based company DeepMind. Founded in 2010 by Demis Hassabis, Shane Legg, and Mustafa Suleyman, DeepMind achieved global recognition for its work on deep reinforcement learning. In 2015, they published a landmark paper in Nature demonstrating an AI agent capable of learning to play Atari 2600 games at a human level directly from sensory input. DeepMind's AlphaGo system subsequently made history in 2016 by defeating Lee Sedol, a world champion Go player, marking a major milestone in AI capabilities.
When both types of loxoscelism do result, systemic effects may occur before necrosis, as the venom spreads throughout the body in minutes. Children, the elderly, and the debilitatingly ill may be more susceptible to systemic loxoscelism. The systemic symptoms most commonly experienced include nausea, vomiting, fever, rashes, and muscle and joint pain. Rarely, such bites can result in hemolysis, low platelet levels, blood clots throughout the body, organ damage, and even death. Most fatalities are in children under the age of seven or those with a weak immune system. While the majority of brown recluse spider bites do not result in any symptoms, cutaneous symptoms occur more frequently than systemic symptoms. In such instances, the bite forms a necrotizing ulcer as the result of soft tissue destruction and may take months to heal, leaving deep scars. These bites usually become painful and itchy within 2–8 hours. Pain and other local effects worsen 12–36 hours after the bite, and the necrosis develops over the next few days. Over time, the wound may grow to as large as 25 cm (10 inches). The damaged tissue becomes gangrenous and eventually sloughs away. L. reclusa can produce slightly more than 0.1 μL of venom, though the average yield is less.
Sources: en.wikipedia.org
=== Delivery costs === In February 2024, Panera settled a class-action lawsuit for $2 million, which accused the company a year beforehand of misleading customers from 2020 to 2021 about its costs for delivery orders. Panera did not admit fault in the settlement.
Local effects: burning or stinging pain, swelling, redness. Severe systemic reactions: swelling of the tongue and throat, difficulty breathing, and shock. Development of optic neuritis and atrophy. Atrial fibrillation, cerebral infarction, acute myocardial infarction, Fisher's syndrome, acute inflammatory polyradiculopathy (Guillain–Barré syndrome), claw hand (through a central action of apamin on the spinal cord and a peripheral action in the form of median and ulnar neuritis, causing spasms of the long flexors in the forearm). Patients poisoned with bee venom can be treated with anti-inflammatory medication, antihistamines and oral prednisolone. Apamin is an element in bee venom. A person can come into contact with apamin through bee venom, so the symptoms that are known are not caused by apamin directly, but by the venom as a whole. Apamin is the only neurotoxin acting purely on the central nervous system. The symptoms of apamin toxicity are not well known, because people are not easily exposed to the toxin alone. Through research about the neurotoxicity of apamin some symptoms were discovered. In mice, the injection of apamin produces convulsions and long-lasting spinal spasticity. Also, it is known that the polysynaptic spinal reflexes are disinhibited in cats. Polysynaptic reflex is a reflex action that transfers an impulse from a sensory neuron to a motor neuron via an interneuron in the spinal cord. In rats, apamin was found to cause tremor and ataxia, as well as dramatic haemorrhagic effects in the lungs.
=== Plastics production === Several widely used polymers contain acrylonitrile as a monomer and therefore incorporate nitrile groups. Pure polyacrylonitrile (PAN) is difficult to process; consequently, during its production, 85 to 99% acrylonitrile is almost always copolymerized with small amounts of other monomers. Copolymers containing 35 to 85% acrylonitrile, together with other monomers such as vinyl acetate and methyl methacrylate, are also employed. Nitrile polymers are among the most important fully synthetic materials for textile fibers, alongside polyesters and polyamidess. These fibers, known as acrylic fibers, are produced on the scale of several million tons per year. In 2000, global production was approximately 2.7 million tons. Acrylic fibers are used in garments (such as socks and sweaters), blankets, carpets, and knitting yarn, among other applications. PAN is also the principal precursor for the production of carbon fiber, which is used as an exceptionally lightweight yet strong material in automotive and aircraft construction. Global production of the monomer acrylonitrile was approximately 3.2 million tons in 1988. Acrylonitrile butadiene rubbers are known as nitrile rubbers and exhibit advantageous properties such as high tensile strength, high abrasion resistance, and resistance to hydrocarbons (oils and fuels). They are therefore used for sealing rings and for oil and fuel hoses.
Molecular clocks have caused controversy due to the dates they derive for events such as explosive radiations seen after extinction events like the Cambrian explosion and the radiations of mammals and birds. Two-fold differences exist in dates derived from molecular clocks and the fossil record. While some paleontologists argue that molecular clocks are systemically inaccurate, others attribute the discrepancies to lack of robust fossil data and bias in sampling. While not without constancy and discrepancies with the fossil record, the data from molecular clocks have shown how evolution is dominated by the mechanisms of a neutral model and is less influenced by the action of natural selection.
Sources: en.wikipedia.org
== Structural aspects == Intrinsically disordered proteins adapt a dynamic range of rapidly interchanging conformations in vivo according to the cell's conditions, creating a structural or conformational ensemble. Their structures are strongly function-related. Few proteins are fully disordered in their native state. Disorder is mostly found in intrinsically disordered regions (IDRs) within an otherwise well-structured protein. The term intrinsically disordered protein (IDP) therefore includes proteins that contain IDRs as well as fully disordered proteins. The existence and kind of protein disorder is encoded in its amino acid sequence. In general, IDPs are characterized by a low content of bulky hydrophobic amino acids and a high proportion of polar and charged amino acids, usually referred to as low hydrophobicity. This property leads to good interactions with water. Furthermore, high net charges promote disorder because of electrostatic repulsion resulting from equally charged residues. Thus disordered sequences cannot sufficiently bury a hydrophobic core to fold into stable globular proteins. In some cases, hydrophobic clusters in disordered sequences provide the clues for identifying the regions that undergo coupled folding and binding (refer to biological roles). Many disordered proteins reveal regions without any regular secondary structure. These regions can be termed as flexible, compared to structured loops. While the latter are rigid and contain only one set of Ramachandran angles, IDPs involve multiple sets of angles.
== History == Biocon was formed in 1978 as Biocon India Private Limited, an India-based partner to the existing Irish multinational brewing enzyme producer Biocon Biochemicals Ltd., with US$10,000 as startup capital from Mazumdar-Shaw. The subsidiary initially produced enzymes for the brewing market such as the papaya enzyme papain and the fish collagen extract Iisinglass, a clarifying agent used for some beers and wines. In 1979, Biocon became the first Indian company to manufacture and export enzymes to the US and Europe, and spent the 1980s producing an increasing share of pharmaceuticals for the domestic market.
The most notable cell types of sponges are the goblet-shaped cells called choanocytes, so named for their similarity to choanoflagellates. The similarities between these two cells types makes scientists believe that choanoflagellates are the sister taxa to metazoa. The flagella of these cells are what drive the water movement through the sponge body. The cell body of choanocytes is what is responsible for nutrient absorption. In some species these cells can develop into gametes. The Pinacocytes are the cells on the exterior of the sponge that line the cell body. They are tightly packed together and very thin. The mesenchyme lines the region between the pinacocytes and the choanocytes. They contain a matrix composed of proteins and spicules. Archaeocytes are special types of cells, in that they can transform into all of the other cell types. They will do what is needed in the sponge body, such as ingest and digest food, transport nutrients to other cells in the sponge body. These cells are also capable of developing into gametes in some sponge species. The sclerocytes are responsible for the secretion of spicules. In species of sponges that use spongin instead of calcaerous and silicaceous spicules, the sclerocytes are replaced by spongocytes, which secrete spongin skeletal fibres. The myocytes and porocytes are responsible for contraction of the sponge. These contractions are analogous to muscle contractions in other organisms, since sponges do not have muscles. They are responsible for regulating the water flow through the sponge.
== Structure == The outer shell of the long bone is made of cortical bone also known as compact bone. This is covered by a membrane of connective tissue called the periosteum. Beneath the cortical bone layer is a layer of spongy cancellous bone. Inside this is the medullary cavity which has an inner core of bone marrow, it contains nutrients and help in formation of cells, made up of yellow marrow in the adult and red marrow in the child.
=== Planting === The sacred lotus requires a nutrient-rich and loam soil. In the beginning of the summer period (from March until May in the northern hemisphere), a small part of rhizome with at least one eye is either planted in ponds or directly into a flooded field. It can also be propagated via seeds or buds. Furthermore, tissue culture is a promising propagation method for the future to produce high volumes of uniform, true-to-type, disease-free materials. The first step of cultivation is to plough the dry field. One round of manure is applied after ten days, before flooding the field. To support a quick initial growth, the water level is relatively low and increases when plants grow. Then a maximum of approximately 4,000 per hectare (1,600/acre) with grid spacing of 1.2 by 2 metres (3 ft 11 in × 6 ft 7 in) are used to plant directly into the mud 10–15 cm (3+7⁄8–5+7⁄8 in) below the soil surface.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.